Chinchilla-López Paulina, Qi Xingshun, Yoshida Eric M, Méndez-Sánchez Nahum
Liver Research Unit. Medica Sur Clinic & Foundation, Mexico City, Mexico.
Department of Gastroenterology, General Hospital of Shenyang Military Area, Shenyang, China.
Ann Hepatol. 2017 May-Jun;16(3):328-330. doi: 10.5604/16652681.1235473.
The increase of incidences of Hepatocellular Carcinoma (HCC) will continue in the next decades. The therapies about hepatitis C infection has been questioned as a risk factor. Some authors emphasized that sustained virologic response (SVR) with interferon-based therapy reduced the risk of developing HCC. In contrast, some publications that to suggest an increasing risk of HCC in patients treated with Direct-Acting Antivirals (DAA). Whether these therapies are associated with an increased risk of HCC remains to be studied and continued long-term observational studies will be needed. The goal in HCV care needs to go beyond merely achieving an SVR.
未来几十年，肝细胞癌（HCC）的发病率将持续上升。丙型肝炎感染的治疗方法被质疑是一个风险因素。一些作者强调，基于干扰素的治疗实现持续病毒学应答（SVR）可降低发生HCC的风险。相比之下，一些出版物表明接受直接抗病毒药物（DAA）治疗的患者发生HCC的风险增加。这些治疗方法是否与HCC风险增加相关仍有待研究，需要持续进行长期观察性研究。丙型肝炎护理的目标需要超越仅仅实现SVR。
Zotero 插件